118 related articles for article (PubMed ID: 31762)
1. New evidence that demonstrates that L-pro-L-leu-L-gly-NH2 might be the natural MIF.
Vivas A; Celis ME
Acta Physiol Lat Am; 1977; 27(4):177-82. PubMed ID: 31762
[TBL] [Abstract][Full Text] [Related]
2. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.
Kastin AJ; Schally AV; Kostrzewa RM
Fed Proc; 1980 Sep; 39(11):2931-6. PubMed ID: 6105977
[TBL] [Abstract][Full Text] [Related]
3. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat.
Bhargava HN; Kim HS
J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229
[TBL] [Abstract][Full Text] [Related]
4. Suppression of ACTH secretion by synthetic MSH-release inhibiting factor Pro-Leu-Gly-NH2 in Addison's disease.
Voigt KH; Fehm HL; Lang RE; Beinert KE; Pfeiffer EF
Horm Metab Res; 1977 Mar; 9(2):150-2. PubMed ID: 16818
[TBL] [Abstract][Full Text] [Related]
5. Effect of the interaction between pro-leu-gly-NH2 and catecholaminergic drugs on MSH release from rat pituitaries incubated in vitro.
Vivas A; Celis ME
Neuroendocrinology; 1982; 35(3):150-4. PubMed ID: 6127639
[TBL] [Abstract][Full Text] [Related]
6. Some questions related to melanocyte-stimulating hormone.
Kastin AJ; Sandman CA; Miller LH; Schally AV
Mayo Clin Proc; 1976 Oct; 51(10):632-6. PubMed ID: 966814
[TBL] [Abstract][Full Text] [Related]
7. Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices.
Scimonelli T; Celis ME
Peptides; 1982; 3(6):885-9. PubMed ID: 6132363
[TBL] [Abstract][Full Text] [Related]
8. Endogenous peptide Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1.
Banks WA; Kastin AJ; Ehrensing CA
J Neurosci Res; 1993 Aug; 35(6):690-5. PubMed ID: 8105102
[TBL] [Abstract][Full Text] [Related]
9. Naloxone-like protective effect of MIF-1 (Pro-Leu-Gly-NH2) on hemorrhagic shock.
Krause W; Nieber K; Ehrlich A; Bienert M; Oehme P
Pharmazie; 1984 May; 39(5):352-3. PubMed ID: 6147863
[No Abstract] [Full Text] [Related]
10. Differences in the release of melanocyte-stimulating hormone in vitro by rat pituitary glands collected at various times during the oestrous cycle.
Vivas A; Celis ME
J Endocrinol; 1978 Jul; 78(1):1-6. PubMed ID: 567239
[TBL] [Abstract][Full Text] [Related]
11. Comparison of in vivo and in vitro corticotropin-releasing hormone-stimulated release of proopiomelanocortin-derived peptides in cats.
Willemse T; Mol JA
Am J Vet Res; 1994 Dec; 55(12):1677-81. PubMed ID: 7887510
[TBL] [Abstract][Full Text] [Related]
12. Structural specificity of MIF-1 and Tyr-MIF-1 in augmenting GABA-stimulated benzodiazepine receptor binding.
Miller LG; Kastin AJ; Roy RB; Gaver A; Fischman AJ; Horvath A
Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):365-8. PubMed ID: 2908009
[TBL] [Abstract][Full Text] [Related]
13. Synthetic MIF has no effect on beta-MSH and ACTH hypersecretion in Nelson's syndrome.
Donnadieu M; Laurent MF; Luton JP; Bricaire H; Girard F; Binoux M
J Clin Endocrinol Metab; 1976 Jun; 42(6):1145-8. PubMed ID: 6486
[TBL] [Abstract][Full Text] [Related]
14. Alpha-MSH and MIF-2 effects on serotonin levels and accumulation in various rat brain areas.
Spirtes MA; Kostrzewa RM; Kastin AJ
Pharmacol Biochem Behav; 1975; 3(6):1011-5. PubMed ID: 4814
[TBL] [Abstract][Full Text] [Related]
15. Structure activity relationship studies with hypothalamic peptide hormones III. Effect of melanotropin-release inhibiting factor and analogs on tolerance to morphine in the rat.
Bhargava HN; Kim HS
Neuropharmacology; 1982 Sep; 21(9):917-22. PubMed ID: 6128692
[TBL] [Abstract][Full Text] [Related]
16. Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
Björkman S; Castensson S; Lindeke B; Sievertsson H
Acta Pharm Suec; 1976; 13(4):289-98. PubMed ID: 11638
[No Abstract] [Full Text] [Related]
17. Inhibition of MSH release from the posterior pituitary lobe incubated in situ induced by acute decrease of arterial blood volume.
Cyrkowicz A
Endokrinologie; 1975 Jul; 65(2):237-9. PubMed ID: 6263
[No Abstract] [Full Text] [Related]
18. MIF-1 facilitates passive avoidance retention.
Puciłowski O; Płaźnik A; Kostowski W
Pol J Pharmacol Pharm; 1982; 34(1-3):107-13. PubMed ID: 6132368
[TBL] [Abstract][Full Text] [Related]
19. MSH activity in the rat pituitary after treatment with Nembutal and morphine: a new bioassay for MSH-release inhibiting factor (MIF).
Kastin AJ; miller MC; Schally AV
Endocrinology; 1968 Jul; 83(1):137-40. PubMed ID: 5659425
[No Abstract] [Full Text] [Related]
20. alpha-MSH and Pro-Leu-Gly-NH2 (PLG; MIF-1): influence on dopamine (DA) uptake in crude synaptosomal preparations from rat mediobasal hypothalamus (MBH) and caudate putamen (CP).
Torre E; Celis ME; Chiocchio SR
Peptides; 1984; 5(4):669-74. PubMed ID: 6149522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
